NCT03198650 - A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 27, 2017

Primary Completion Date

October 27, 2022

Study Completion Date

December 31, 2025

Conditions

Part1: Advanced B-cell MalignanciesPart2: r/rCLL and r/rMCLPart3: Untreated CLL

Interventions

DRUG

Acalabrutinib

DRUG

Obinutuzumab

Trial Locations (14)

Research Site, Chiba

Research Site, Chūōku

Research Site, Fukuoka

Research Site, Isehara-shi

Research Site, Izumo-shi

Research Site, Matsuyama

Research Site, Nagoya

Research Site, Nagoya

Research Site, Niigata

Research Site, Okayama

Research Site, Sapporo

Research Site, Sendai

Research Site, Shimotsuke-shi

Research Site, Suita-shi